👇🏼 Every word is true. Come take care of sarcoma patients with us.

After travelling to Chicago for scientific meetings at least 20 times I finally discovered by chance my own roots on Lincoln Ave…unglaublich!

The IDRX-42 GIST story: yet another example of reverse translation of our in vivo work with patient-derived mouse xenografts in the Lab of Experimental Oncology at KU Leuven providing a rationale for a clinical application. See De Sutter et al DOI: 10.1158/1078-0432.CCR-22-3822

IDRX-42: next generation KIT inhibitor for treatment of gastrointestinal stromal tumor. Convincing safety profile and strong efficacy signal during Phase 1 dose escalation and recruitment ongoing in Phase 1b. Send your patients (all lines) to active sites! See ASCO 2024 #11501

Yesterday I defended my doctoral thesis on the biology and drug sensitivity of selected mesenchymal malignancies. I am very grateful Patrick Schöffski, Aga Wozniak and Daphne Hompes for these past four years and I am looking forward to the next adventures on my path…

The sheer number and rapid increase in the number of (often duplicative) mandatory online training modules for clinical care, research, and institutional employment is completely unsustainable ⁦AMA⁩ ama-assn.org/practice-manag…

Op 1-8-2024 wordt prof. Paul Herijgers de nieuwe gedelegeerd bestuurder van UZ Leuven. Huidig CEO prof. Wim Robberecht: 'Paul Herijgers kan bogen op zijn ervaring als vermaard chirurg in ons ziekenhuis en als gedreven decaan van de faculteit geneeskunde.'
bit.ly/3UdV1wQ

ONO Pharmaceutical acquired Deciphera Pharmaceutical, Inc. Thanks to Deciphera for developing essential drugs for treatment or rare, important diseases such as GIST and tenosynovial giant cell tumor and thanks for the close interaction with the sarcoma community over the years

ASCO has finally launched the new membership model, which provides full access to educational resources, career development plans, multiple journals and discounted access to the Annual Meeting to the members. Join ASCO today! asco.org

SpringWorks applied for EMA approval of nirogacestat for adult desmoid fibromatosis.Believe it or not: at present no drug has EU marketing authorization for this disease, which causes significant morbidity in our patients. Let‘s make off label use of drugs in this setting history

What an amazing accomplishment! Kudos to Jason Sicklick and all of the doctors involved in this publication!

PEComa - to me one of the most enigmatic subtypes of soft tissue sarcoma: development of a new prognostic score discriminating between indolent and malignant variants. Read Gantzer et al. doi.org/10.1002/cncr.3…

This week at British Sarcoma Group conference, we honoured Prof. Judson with the Shining Star Lifetime Achievement Award, presented to him by @amocras.

Read Prof. Judson's speech here.
sarcoma.org.uk/get-involved/s…

Good news for patients with #desmoids in Europe: Springworks just announced the submission of #nirogacestat to the EMA. Read the official press release here: ir.springworkstx.com/news-releases/…

SpringWorks #aggressivefibromatosis #sarcoma

In The Lancet : Sunitinib is an option in pts w mets phaeochromocytomas and paragangliomas : 36% of pts free of progressive disease at 12 months. 1st randomized trial ever in this disease, by E Baudin Gustave Roussy and col ENDOCAN-COMET & ENSAT networks. thelancet.com/journals/lance…

Optical Genome Mapping, a fascinating new diagnostic tool for comprehensive cytogenetic analysis for sarcomas. Read Baelen J et al. doi.org/10.1016/j.jmol…

Exploratory analysis from the phase III INTRIGUE study points to the prospects of liquid biopsy in guiding patient selection for targeted therapy and personalized medicine in advanced #GIST . 

🗞️The results have recently been published in Nature Medicine 👉linke.to/INTRIGUEVHIO

CONDOR 2024 in Bordeaux: THE meeting for people interested in the sarcoma microenvironment and immunotherapy. Check condorprogram.com/symposium-2nd-…

Vesalius‘ book ‚De humani corporis fabrica' with his personal notes comes back to his alma mater, KU Leuven. What a present for the academic community on the occasion of our 600th birthday next year. Spectacular! nieuws.kuleuven.be/nl/2024/de-hum…

Brigimadlin (BI-907828) efficacious in GBM pre-clinical models Molecular Cancer Therapeutics
Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant In Vivo Efficacy in Glioblastoma aacrjournals.org/mct/article-ab…